Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XERS Stock Forecast 2026-2027
$8.28
Current Price
$1.43B
Market Cap
Buy 6
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to XERS Price Targets
+117.4%
To High Target of $18.00
+20.8%
To Median Target of $10.00
-3.4%
To Low Target of $8.00
XERS Price Momentum
-3.9%
1 Week Change
+20.0%
1 Month Change
+57.4%
1 Year Change
+5.5%
Year-to-Date Change
-17.9%
From 52W High of $10.08
+70.0%
From 52W Low of $4.87
📊 TOP ANALYST CALLS
Did XERS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Xeris is one of their latest high-conviction picks.
Latest XERS Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, XERS has a bullish consensus with a median price target of $10.00 (ranging from $8.00 to $18.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $8.28, the median forecast implies a 20.8% upside. This outlook is supported by 6 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XERS Analyst Ratings
6
Buy
1
Hold
0
Sell
XERS Price Target Range
Low
$8.00
Average
$10.00
High
$18.00
Current: $8.28
Latest XERS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XERS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 2, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $10.00 |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 9, 2025 | Barclays | Overweight | Initiates | $N/A | |
| Nov 7, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Nov 7, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 7, 2025 | Piper Sandler | Neutral | Maintains | $N/A | |
| Oct 29, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Sep 17, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Aug 19, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| Aug 12, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $10.00 |
| Aug 8, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| Aug 8, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Jun 5, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| May 9, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Mar 7, 2025 | Piper Sandler | Neutral | Reiterates | $N/A | |
| Mar 7, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| Mar 7, 2025 | Craig-Hallum | Buy | Maintains | $N/A | |
| Mar 7, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 29, 2025 | Jefferies | Buy | Reiterates | $N/A | |
| Nov 11, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Xeris Biopharma Holdings, Inc. (XERS) Competitors
The following stocks are similar to Xeris based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xeris Biopharma Holdings, Inc. (XERS) Financial Data
Xeris Biopharma Holdings, Inc. has a market capitalization of $1.43B with a P/E ratio of 116.6x. The company generates $314.85M in trailing twelve-month revenue with a 3.8% profit margin.
Revenue growth is +38.3% quarter-over-quarter, while maintaining an operating margin of +9.5% and return on equity of +4.0%.
Valuation Metrics
Market Cap
$1.43B
Enterprise Value
$1.56B
P/E Ratio
116.6x
PEG Ratio
-1.0x
Price/Sales
4.5x
Growth & Margins
Revenue Growth (YoY)
+38.3%
Gross Margin
+87.3%
Operating Margin
+9.5%
Net Margin
+3.8%
EPS Growth
+38.3%
Financial Health
Cash/Price Ratio
+7.8%
Current Ratio
2.1x
Debt/Equity
1,987.2x
ROE
+4.0%
ROA
+6.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Xeris Biopharma Holdings, Inc. (XERS) Business Model
About Xeris Biopharma Holdings, Inc.
What They Do
Develops therapies for chronic endocrine and neurological conditions.
Business Model
Xeris Biopharma Holdings generates revenue through the commercialization of its therapies, including Recorlev, Gvoke, and Keveyis. The company utilizes its proprietary formulation platforms, XeriSol and XeriJect, to create innovative delivery systems that enhance patient access and compliance. Partnerships, such as the recent collaboration with American Regent for Gvoke VialDx, also contribute to its business model by expanding product offerings and market reach.
Additional Information
With a strong focus on rare disease treatments, Xeris maintains an active pipeline, including XP-8121, which has received recent U.S. patent allowances. The company emphasizes intellectual property protection and aims for commercial expansion within the U.S. market, positioning itself as a significant player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
394
CEO
Mr. John P. Shannon
Country
United States
IPO Year
2018
Website
www.xerispharma.comXeris Biopharma Holdings, Inc. (XERS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?
Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Jul 08, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Xeris Biopharma (XERS) saw increased trading volume recently, but recent earnings estimate revisions suggest that upward momentum may not continue soon.
Why It Matters
Xeris Biopharma's increased trading volume signals heightened investor interest, but negative earnings estimate revisions may suggest potential challenges ahead for the stock's performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Xeris Biopharma granted 221,323 restricted stock units to 47 new employees on July 1, 2026, under its Inducement Equity Plan to support growth in its biopharmaceutical initiatives.
Why It Matters
The grant of restricted stock units indicates Xeris Biopharma's growth strategy and commitment to attracting talent, potentially enhancing future performance and shareholder value.
Source: Business Wire
Market Sentiment:
Neutral
CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
13 days ago
Quick Summary
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) announced inducement grants under NASDAQ listing rule 5635(c)(4) in a corrected release, providing additional details on the grants.
Why It Matters
Xeris Biopharma's inducement grants signal potential growth and strategic initiatives, which may impact stock performance and investor confidence in its future.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Xeris has announced updates to its Board of Directors, which may impact corporate governance and strategic direction. Investors should monitor further developments.
Why It Matters
Board changes can signal shifts in corporate strategy or governance, impacting investor confidence and future performance. New leadership may influence company direction and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Xeris Biopharma Holdings, Inc. has entered into exchange agreements with holders of its 8.00% Convertible Senior Notes due 2028, pending customary closing conditions.
Why It Matters
Xeris Biopharma’s exchange of convertible notes may improve liquidity and reduce debt, potentially enhancing financial stability and growth prospects, which can positively influence stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Xeris Pharmaceuticals, a subsidiary of Biopharma Holdings, has received a Notice of Allowance from the USPTO for a patent on compositions and methods of use, indicating potential advancements in their product development.
Why It Matters
The patent allowance enhances Xeris Pharmaceuticals' competitive edge, potentially leading to increased revenue and market value, attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About XERS Stock
What is Xeris Biopharma Holdings, Inc.'s (XERS) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Xeris Biopharma Holdings, Inc. (XERS) has a median price target of $10.00. The highest price target is $18.00 and the lowest is $8.00.
Is XERS stock a good investment in 2027?
According to current analyst ratings, XERS has 6 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.28. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XERS stock?
Wall Street analysts predict XERS stock could reach $10.00 in the next 12 months. This represents a 20.8% increase from the current price of $8.28. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xeris Biopharma Holdings, Inc.'s business model?
Xeris Biopharma Holdings generates revenue through the commercialization of its therapies, including Recorlev, Gvoke, and Keveyis. The company utilizes its proprietary formulation platforms, XeriSol and XeriJect, to create innovative delivery systems that enhance patient access and compliance. Partnerships, such as the recent collaboration with American Regent for Gvoke VialDx, also contribute to its business model by expanding product offerings and market reach.
What is the highest forecasted price for XERS Xeris Biopharma Holdings, Inc.?
Price targets from Wall Street analysts for XERS are not currently available. The stock is trading at $8.28.
What is the lowest forecasted price for XERS Xeris Biopharma Holdings, Inc.?
The lowest price target for XERS is $8.00 from at , which represents a -3.4% decrease from the current price of $8.28.
What is the overall XERS consensus from analysts for Xeris Biopharma Holdings, Inc.?
The overall analyst consensus for XERS is bullish. Out of 4 Wall Street analysts, 6 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are XERS stock price projections?
Stock price projections, including those for Xeris Biopharma Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 15, 2026 7:43 PM UTC